Neogen (NEOG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$11.83+1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NEOG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks NEOG against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute the multi-quarter manufacturing transition of Petrifilm to the Lansing site, with first fully validated SKU expected by end of August 2026 and transition completion by November 2026.
Stated as a priority in 3 of last 3 quarters. Management consistently reports the Petrifilm manufacturing transition is on track for completion by November 2026, with operational and performance validations progressing and first fully validated SKU expected by end of August 2026. The trajectory is delivering as planned with no reported delays.
“Petrifilm manufacturing transition remains on track for November FY27; operational and performance validation on multiple SKUs underway.”
“Company advanced transition to new Petrifilm manufacturing line; completed validation on 100% of equipment and engaged in operational validation of SKUs.”
“Petrifilm manufacturing transition remains on track for November FY27; initiated operational and performance validation on multiple SKUs.”
Complete the sale of the global Genomics business to Zoetis Inc. by the end of the first half of fiscal year 2027, with net proceeds used primarily for debt reduction.
Stated as a priority in 3 of last 3 quarters. Management has consistently communicated the planned divestiture of the Genomics business to Zoetis Inc. by 2Q27, with expected net proceeds of approximately $140 million to be used primarily for debt reduction. The transaction is under regulatory review with no reported delays, indicating progress is on track.
Raise fiscal year 2026 revenue guidance to a range of $857 million to $860 million while maintaining adjusted EBITDA guidance of approximately $175 million.
Stated as a priority in 2 of last 2 quarters. Management raised FY26 revenue guidance from $845-$855 million to $857-$860 million while maintaining adjusted EBITDA guidance at approximately $175 million. Revenue for FY26 was $870.4 million, slightly above guidance, indicating delivery on the raised revenue target.
Focus on growing Food Safety segment revenue through strong core growth, especially in Indicator Testing, Culture Media, and Bacterial & General Sanitation product categories.
Stated as a priority in 3 of last 3 quarters. Food Safety segment revenue showed growth of 3.1% in Q4 FY26 to $166.8 million with core growth of 5.8%, the highest since FY23. Earlier quarters showed mixed results with some declines in Q1 FY26 but recovery in Q3 and Q4. The trajectory shows delivering growth in Food Safety.
“Food Safety revenue growth of 2.6%, Core Growth of 4.0% in Q3 FY26.”
Implement cost-saving initiatives and operational improvements to enhance adjusted EBITDA margins and reduce operating expenses.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin improved from 18.0% in Q4 FY25 to 20.2% in Q4 FY26, reflecting cost saving initiatives implemented since Q1 FY26. Sequential margin improvement in Q3 FY26 further supports progress. The trajectory is delivering operational efficiency gains.
Over the trailing year it converted 3.95x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Divestiture of Genomics business unit announced and anticipated to close in 2Q27; net proceeds support debt reduction.”
“Neogen is working toward completing sale of global Genomics business to Zoetis by end of first half of fiscal 2027; net proceeds approx. $140 million.”
“Entered definitive agreement to sell global Genomics business to Zoetis for $160 million; expected to close by end of 2Q FY27.”
“Raising fiscal year 2026 revenue outlook to $857-$860 million and maintaining Adjusted EBITDA guidance.”
“The Company is raising its full-year outlook for fiscal year 2026. Revenue is anticipated to be in the range of $845 million to $855 million.”
“Food Safety segment revenue was $152.1 million, a decrease of 4.6%, with core revenue decline of 1.7%.”
“Food Safety revenue was $156.7 million in Q3, increasing 2.6% YoY; core Food Safety revenue increased 4.0%.”
“Adjusted EBITDA margin was 22.8% in Q3 FY26, up 110 basis points sequentially due to cost saving initiatives.”
“Adjusted EBITDA margin was 17.0% in Q1 FY26, lower than prior year due to gross margin decline and higher expenses.”
“Strong adjusted EBITDA through solid cost control despite supply challenges.”